These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 10763461)

  • 1. Vasoactive intestinal peptide/phentolamine. Invicorp, vasopotin.
    Drugs R D; 1999 Dec; 2(6):436-8. PubMed ID: 10763461
    [No Abstract]   [Full Text] [Related]  

  • 2. Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction.
    Dinsmore WW; Wyllie MG
    BJU Int; 2008 Sep; 102(8):933-7. PubMed ID: 18485029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anatomy of drug development: Invicorp, a product before its time.
    Wyllie MG
    BJU Int; 2010 Sep; 106(5):723-4. PubMed ID: 21050351
    [No Abstract]   [Full Text] [Related]  

  • 4. Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate.
    Shah PJ; Dinsmore W; Oakes RA; Hackett G
    Curr Med Res Opin; 2007 Oct; 23(10):2577-83. PubMed ID: 17875241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction.
    McMahon CG
    Int J Impot Res; 1996 Dec; 8(4):233-6. PubMed ID: 8981173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phenotolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction.
    Sandhu D; Curless E; Dean J; Hackett G; Liu S; Savage D; Oakes R; Frentz G
    Int J Impot Res; 1999 Apr; 11(2):91-7. PubMed ID: 10356669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aviptadil (Senatek).
    Keijzers GB
    Curr Opin Investig Drugs; 2001 Apr; 2(4):545-9. PubMed ID: 11566015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure.
    Gerstenberg TC; Metz P; Ottesen B; Fahrenkrug J
    J Urol; 1992 May; 147(5):1277-9. PubMed ID: 1569667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intracavernous infusion of drugs].
    Bellorofonte C; Dell'Acqua S; Ruoppolo M; Zaatar C; Tombolini P
    Arch Ital Urol Nefrol Androl; 1992 Sep; 64(3):251-4. PubMed ID: 1439852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents.
    Dinsmore WW; Alderdice DK
    Br J Urol; 1998 Mar; 81(3):437-40. PubMed ID: 9523666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and therapeutic technology assessment. Vasoactive intracavernous pharmacotherapy for impotence: papaverine and phentolamine.
    JAMA; 1990 Aug; 264(6):752-4. PubMed ID: 2374280
    [No Abstract]   [Full Text] [Related]  

  • 12. Intracavernous injection of vasoactive drugs, an alternative for treating impotence in spinal cord injury patients.
    Wyndaele JJ; de Meyer JM; de Sy WA; Claessens H
    Paraplegia; 1986 Oct; 24(5):271-5. PubMed ID: 3774363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
    Asuar Aydillo S
    Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
    [No Abstract]   [Full Text] [Related]  

  • 14. [Topical treatment of erectile dysfunction. Possibilities and perspectives].
    Pastorini S; Cocimano V; Pugno E; Marten Perolino R
    Arch Ital Urol Androl; 1995 Dec; 67(5):299-302. PubMed ID: 8589743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Percutaneous use of vasoactive drugs in the diagnosis and treatment of erectile impotence].
    Pastorini S; Marino G; Cocimano V; Marten Perolino R
    Minerva Urol Nefrol; 1992; 44(3):191-3. PubMed ID: 1492270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy for erectile dysfunction: a randomized, double blind, unblinded active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate and papaverine hydrochloride in men with moderate to severe erectile dysfunction.
    Lammers PI; Rubio-Aurioles E; Castell R; Castaneda J; Ponce de Leon R; Hurley D; Lipezker M; Loehr LA; Lowrey F
    Int J Impot Res; 2002 Feb; 14(1):54-9; discussion 60. PubMed ID: 11896479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future directions in erectile dysfunction therapy.
    Mulhall JP
    Postgrad Med; 2000 May; 107(6 Suppl Educational):19-23. PubMed ID: 19667519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of vasoactive agents in the treatment of erectile impotence.
    Fried FA
    N C Med J; 1990 Jun; 51(6):295-6. PubMed ID: 2366889
    [No Abstract]   [Full Text] [Related]  

  • 19. It's there in three colours for all to see!
    Wyllie MG
    BJU Int; 2008 Nov; 102(9):1175-6. PubMed ID: 19035908
    [No Abstract]   [Full Text] [Related]  

  • 20. Medical treatment of impotence with papaverine and phentolamine intracavernosal injection.
    Dinsmore WW
    Ulster Med J; 1990 Oct; 59(2):174-6. PubMed ID: 2278115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.